$16.60 -$0.19 (-1.1%)

12:02 PM EDT on 04/26/19

Intellia Therapeutics, Inc. (NASDAQ:NTLA)

CAPS Rating: 4 out of 5

Current Price $16.60 Mkt Cap $0.00
Open $16.94 P/E Ratio 0.00
Prev. Close $16.79 Div. (Yield) $0.00 (0.0%)
Daily Range $16.50 - $16.94 Volume 51,650
52-Wk Range $12.68 - $18.65 Avg. Daily Vol.

Caps

How do you think NASDAQ:NTLA will perform against the market?

Add Stock to CAPS Watchlist

All Players

56 Outperform
2 Underperform
 

All-Star Players

23 Outperform
0 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top NASDAQ:NTLA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

OceanJackson (< 20)
Submitted May 10, 2016

While the CRISPR patent dispute is happening, the hype will drive this one higher within the next couple months.

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:NTLA VS S&P 500 (SPY)

NASDAQ:NTLA Summary

Fools bullish on NASDAQ:NTLA are also bullish on:

Fools bearish on NASDAQ:NTLA are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about NTLA.

Recs

0
Member Avatar JohnCLeven (21.95) Submitted: 8/24/2018 3:57:41 PM : Outperform Start Price: $28.73 NASDAQ:NTLA Score: -43.57

Taking a flier on the 3 public CRISPR related stocks. All three combined at valued <$5B which seems low considering the future of gene editing in healthcare. All 3 could be worthless, but I wouldn't be shocked if one of these ends up a 100X bagger someday.

Recs

0
Member Avatar InvestRight (90.48) Submitted: 6/13/2018 10:00:03 AM : Outperform Start Price: $24.94 NASDAQ:NTLA Score: -37.78

Recent 11% drop is unwarranted and now is the time to buy into CRISPR stocks. Outperform.

Recs

0
Member Avatar XMFRendezvous (94.42) Submitted: 4/20/2018 12:24:20 AM : Outperform Start Price: $21.80 NASDAQ:NTLA Score: -32.15

The ability to pick which one of these Gene Editing companies is beyond my knowledge, but what I do know is this is likely to be a highly transformative technology and genetics is likely to be the future of medicine. Seeing any fundamentals will take some time. Citi group projects that CRISPR will be a 10B market by 2025, which is peanuts compared to the long-term potential. Let it ride and forget about it. Volatility expected. Now seems like a fair value to get in.

Leaderboard

Find the members with the highest scoring picks in NTLA.

Score Leader

sln

sln (69.20) Score: +66.71

The Score Leader is the player with the highest score across all their picks in NTLA.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
clangmead 24.72 12/28/2018 Outperform 5Y $12.51 +33.65% +17.69% +15.96 0 Comment
SuntanSuperman 99.82 2/25/2019 Outperform 5Y $14.02 +19.26% +4.23% +15.03 0 Comment
CMFMLove 43.35 6/13/2017 Outperform 5Y $12.67 +31.97% +19.93% +12.04 1 Comment
NextGenStock < 20 1/14/2019 Outperform 5Y $13.94 +19.94% +13.91% +6.03 0 Comment
UltraLong18 31.64 1/14/2019 Outperform 5Y $13.94 +19.94% +13.91% +6.03 0 Comment
stereotyp72 53.01 1/24/2017 Outperform 5Y $12.48 +33.97% +29.24% +4.73 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. afalk42 81.79 12/21/2018 Outperform 5Y $13.76 +21.51% +18.59% +2.93 0 Comment
prankjt17530 45.97 2/13/2017 Outperform 5Y $13.02 +28.42% +26.08% +2.34 0 Comment
Playa14 < 20 1/18/2019 Outperform 5Y $14.99 +11.54% +10.42% +1.12 0 Comment
shonny2 < 20 1/7/2019 Outperform 5Y $14.35 +16.52% +15.79% +0.72 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
trackchardan 61.73 5/15/2018 Outperform NS $25.07 -33.31% +7.74% -41.04 0 Comment

Advertisement